Literature DB >> 19064622

Real-world therapies and the problem of vivax malaria.

J Kevin Baird.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19064622     DOI： 10.1056/NEJMe0808729

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

1.  Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes.

Authors:  Neekesh V Dharia; A Taylor Bright; Scott J Westenberger; S Whitney Barnes; Serge Batalov; Kelli Kuhen; Rachel Borboa; Glenn C Federe; Colleen M McClean; Joseph M Vinetz; Victor Neyra; Alejandro Llanos-Cuentas; John W Barnwell; John R Walker; Elizabeth A Winzeler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-29       Impact factor: 11.205

2.  Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.

Authors:  Sam Salman; Susan Griffin; Kay Kose; Nolene Pitus; Josephine Winmai; Brioni Moore; Peter Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 3.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

4.  Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea.

Authors:  Wendy A Davis; Philip M Clarke; Peter M Siba; Harin A Karunajeewa; Carol Davy; Ivo Mueller; Timothy M E Davis
Journal:  Bull World Health Organ       Date:  2011-02-01       Impact factor: 9.408

Review 5.  Using genetic methods to define the targets of compounds with antimalarial activity.

Authors:  Erika L Flannery; David A Fidock; Elizabeth A Winzeler
Journal:  J Med Chem       Date:  2013-09-06       Impact factor: 7.446

Review 6.  Malaria biology and disease pathogenesis: insights for new treatments.

Authors:  Louis H Miller; Hans C Ackerman; Xin-zhuan Su; Thomas E Wellems
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

7.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

8.  Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood.

Authors:  Kanlaya Sriprawat; Supaporn Kaewpongsri; Rossarin Suwanarusk; Mara L Leimanis; Usa Lek-Uthai; Aung Pyae Phyo; Georges Snounou; Bruce Russell; Laurent Renia; François Nosten
Journal:  Malar J       Date:  2009-06-02       Impact factor: 2.979

9.  In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.

Authors:  Swagata Ganguly; Pabitra Saha; Subhasish K Guha; Sonali Das; Dilip K Bera; Asit Biswas; Pratip K Kundu; Bibhuti Saha; Krishnangshu Ray; Ardhendu K Maji
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

10.  Chemotherapeutics challenges in developing effective treatments for the endemic malarias.

Authors:  J Kevin Baird
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-02-17       Impact factor: 4.077
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.